AACR Conference: Redefining Lung Cancer: From Mechanistic Biology to Emerging and AI‑Driven Therapies

Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.

Home > Cancer Researchers / Other Health Care Professionals > Meetings > Meeting > AACR Conference: Redefining Lung Cancer: From Mechanistic Biology to Emerging and AI‑Driven Therapies

Christine D. Berg, Early Cancer Detection Consultant, NCI (retired), Bethesda, Maryland Ramaswamy Govindan, Washington University School of Medicine in St. Louis, St. Louis, Missouri Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York Katerina A. Politi, Yale Cancer Center, New Haven, Connecticut Charles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, New York Monte M. Winslow, Stanford University, Stanford, California Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

This inaugural meeting of the AACR Lung Cancer Task Force brings together an exceptionally distinguished and internationally recognized leadership group, reflecting the depth and breadth of expertise driving progress in the field. Designed as a highly curated, multidisciplinary forum, the program convenes leading researchers, clinicians, and innovators to address the most pressing challenges in lung cancer.

Over three days, the meeting will span the full continuum of discovery and care, from prevention, risk assessment, and early detection to translational science and emerging therapeutic strategies. Plenary sessions will explore key areas including minimal residual disease, clinical trial innovation, immuno‑oncology, oncogene‑driven disease, and small cell lung cancer.

Attendees will gain insights into advances in lung tumor biology, resistance mechanisms, and precision medicine, alongside the integration of technologies such as genomics and artificial intelligence. Featuring expert speakers and interactive discussions, the meeting aims to foster collaboration and accelerate progress toward improving outcomes for lung cancer patients worldwide.